These findings demonstrate that FRA1 enhances melanoma metastasis at least in part by transcriptionally activating AXL, CDK6, and FSCN1, and targeting CDK4/6 and Fascin could be explored as a therapeutic strategy for FRA1-high metastatic melanoma. Here, FSCN1 is linked to metastatic melanoma.